Business Context and Reporting Period
This Form 8-K, dated July 26, 2019, reports material definitive agreements and unregistered sales of equity securities by BioRestorative Therapies, Inc. The filing details a proposed capital raise and debt restructuring contingent upon a public offering and Nasdaq listing approval.
Key Financial Metrics and Agreements
- Proposed Financing: Agreement with Arena Investors LP for $5,400,000 in consideration for 5,500,000 shares of Series A preferred stock, a warrant for 6,000,000 common shares, and a $500,000 convertible promissory note.
- Debt Instruments:
- Arena Note: $500,000 principal, 12% annual interest, 18-month maturity, secured by company assets.
- Recent Convertible Notes: $570,000 principal issued between July 18-22, 2019, for $518,500 cash proceeds (12% interest).
- Debt Exchanges: Agreements to exchange $675,000 of existing debt and $675,000 of debt held by director John M. Desmarais and Tuxis Trust for equity/warrants upon a public offering.
- Recent Equity/Debt Activity:
- Issued 674,858 common shares for $110,503 of indebtedness (July 24 - Aug 1, 2019).
- Repaid $229,760 of convertible notes (July 31 - Aug 1, 2019).
- Liquidity: The filing does not provide a clear value for total cash on hand or working capital as of the report date.
Material Changes and Conditions
The closing of the Arena Investors agreement is subject to three primary conditions: stockholder approval, execution of an underwriting agreement for a public offering with at least $7,500,000 in gross proceeds, and Nasdaq listing approval. The transaction involves a significant dilution mechanism, with Series A preferred stock convertible at 75% of the public offering price and warrants exercisable at 125% of that conversion price.
Outlook, Risks, and Contingencies
- Contingent Closing: The $5.4 million investment is not guaranteed and depends on the successful completion of a public offering and regulatory approvals.
- Liquidated Damages: If the company fails to file or maintain an effective registration statement for Arena's securities within specified timelines (50 days to file, 135 days to effectiveness), it must pay liquidated damages of 1% per month (capped at 8%) of the aggregate amount paid by Arena.
- Redemption and Prepayment: The company may redeem Series A preferred stock with a 25% premium or prepay the Arena Note with a 30% premium, subject to conditions.
- Related Party Transactions: Significant debt held by director John M. Desmarais and his trust is being restructured with favorable terms (warrant exercise price reduction to $0.75) contingent on stockholder approval.
Investor Verification Checklist
- Confirm whether the required public offering of at least $7,500,000 has been executed and closed.
- Verify if Nasdaq has approved the company's listing application.
- Check for stockholder approval of the Arena Purchase Agreement and the related party debt exchanges.
- Review the final terms of the public offering to calculate the actual conversion price of the Series A preferred stock and the exercise price of the warrants.
- Assess the company's current cash position to determine if it can sustain operations pending the closing of the Arena transaction.